Shares of Kura Oncology Inc. (NASDAQ:KURA) traded down 1.3% during mid-day trading on Friday . The stock traded as low as $4.91 and last traded at $5.33, with a volume of 3,307,284 shares trading hands. The stock had previously closed at $5.26.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Wednesday. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st. Finally, Citigroup Inc. decreased their target price on Kura Oncology from $19.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, March 21st.

The stock’s market cap is $95.70 million. The stock has a 50-day moving average price of $3.05 and a 200-day moving average price of $3.95.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. Analysts expect that Kura Oncology Inc. will post ($1.70) earnings per share for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.